L-arginine does not reverse impaired agonist-induced increases in macromolecular efflux during diabetes mellitus

Cardiovascular Research

Volumn 34, Issue 1, 1997, Pages 215-222

  Mayhan, William G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cheek pouch; Diabetes; Hamster; Histamine; Immunofluorescence; L Arginine; Nitric oxide; Permeability; Substance P

Indexed keywords

ARGININE; HISTAMINE; NITRIC OXIDE SYNTHASE; SUBSTANCE P;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; HAMSTER; INTRACELLULAR TRANSPORT; MACROMOLECULE; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

ANIMALS; ARGININE; CAPILLARY PERMEABILITY; CHEEK; CRICETINAE; DEXTRANS; DIABETES MELLITUS, EXPERIMENTAL; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FLUORESCEIN-5-ISOTHIOCYANATE; HISTAMINE; INFLAMMATION MEDIATORS; MACROMOLECULAR SUBSTANCES; MALE; MESOCRICETUS; SUBSTANCE P;

EID: 0030950778     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00013-8     Document Type: Article

References (74)

1. Mayhan WG. Cerebral circulation during diabetes mellitus. Pharmacol Ther 1993;57:377-391.
2. Johnson PC, Brendel K, Meezan E Thickened cerebral cortical capillary basement membranes in diabetes. Arch Pathol Lab Med 1982;106:214-217.
3. Bohlen HG, Niggl BA. Arteriolar anatomical and functional abnormalities in juvenile mice with genetic or streptozotocin induced diabetes mellitus. Circ Res 1979;45:390-396.
4. Colwell JA, Halushka PV, Sarji KE, Lopes-Virella MF, Sagel J. Vascular diseases in diabetes: pathophysiological mechanisms and therapy. Arch Intern Med 1979;139:225-230.
5. Joyner WL, Mayhan WG, Johnson RL, Phares CK. Microvascular alterations develop in Syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes 1981;30:93-100.
6. Parving H. Increased microvascular permeability to plasma proteins in short- and long-term juvenile diabetes. Diabetes 1976;25:884-889.
7. Tooke JE. Microcirculation and diabetes. Br Med Bull 1989;45:206-223.
8. Colantuoni A, Berardi PG, Orefice G. Increased permeability of the microcirculation to high molecular weight dextran in experimental diabetes, shown by intravital microfluorimetry. J Nucl Med Allied Sci 1979;23:49-54.
9. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992;44:103-150.
10. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992;20:253-263.
11. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-1685.
12. Pieper, GM, Gross, GJ. Endothelial dysfunction in diabetes. In: Rubanyi GM, ed. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. Mount Kisco, NY: Futura Publishing Co., 1991:223-249.
13. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992;6:2905-2914.
14. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.
15. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-2554.
16. Ralevic V, Khalil Z, Helme RD, Dusting GJ. Role of nitric oxide in the actions of substance P and other mediators of inflammation in rat skin microvasculature. Eur J Pharmacol 1995;284:231-239.
17. Hughes SR, Williams TJ, Brain SD. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur J Pharmacol 1990;191:481-484.
18. Mayhan WG, Joyner WL. The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc Res 1984;28:159-179.
19. Joyner WL, Carter RD, Raizes GS, Renkin EM. Influence of histamine and some other substances on blood-lymph transport of plasma protein and dextran in the dog paw. Microvasc Res 1974;7:19-30.
20. Carter RD, Joyner WL, Renkin EM. Effects of histamine and some other substances on molecular selectivity of the capillary wall to plasma protein and dextran. Microvasc Res 1974;7:31-48.
21. Majno G, Palade GE. Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol 1961;11:571-605.
22. Majno G, Gilmore V, Leventhal M. On the mechanism of vascular leakage caused by histamine-type mediators. Circ Res 1967;21:833-847.
23. Majno G, Shea SM, Leventhal M. Endothelial contraction produced by histamine-type mediators. J Cell Biol 1969;42:647-672.
24. Mayhan WG. Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am J Physiol 1994;266:H2369-H2373.
25. 4-induced increases in microvascular transport. Am J Physiol 1993;265:H409-H414.
26. Mayhan WG. Role of nitric oxide in modulating permeability of the hamster cheek pouch in response to adenosine 5′-diphosphate and bradykinin. Inflammation 1992;16:295-305.
27. Yuan Y, Granger HJ, Zawieja DC, Chilian WM. Flow modulates coronary venular permeability by a nitric oxide-related mechanism. Am J Physiol 1992;263:H641-H646.
28. Ialenti A, Ianaro A, Moncada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 1992;211:177-182.
29. Yuan Y, Granger HJ, Zawieja DC, DeFily DV, Chilian WM. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. Am J Physiol 1993;264:H1734-H1739.
30. Ziehe M, Morbidelli L, Parenti A, Amerini S, Granger HJ, Maggi CA. Substance P increases cyclic GMP levels on coronary postcapillary venular endothelial cells. Life Sci 1993;53:229-234.
31. Garcia-Leme J, Bohm GM, Migliorini RH, De Souza MZA. Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 1974;29:298-306.
32. Alsip NL, Schuschke DA, Wead WB, Harris PD. Alteration of microvascular responses to serotonin in the diabetic rat. Int J Microcirc Clin Exp 1992;11:263-275.
33. Llorach MAS, Bohm GM, Garcia-Leme J. Decreased vascular reactions to permeability factors in experimental diabetes. Br J Exp Pathol 1976;57:747-754.
34. Garcia-Leme J, Hamamura L, Migliorini RH, Leite MP. Influence of diabetes upon the inflammatory response of the rat: a pharmacological analysis. Eur J Pharmacol 1973;23:74-81.
35. Phares CK. Streptozotocin-induced diabetes in Syrian hamsters: new model of diabetes mellitus. Experientia 1980;36:681-682.
36. Mayhan WG, Sahagun G, Spector R, Heistad DD. Effects of leukotriene C4 on the cerebral microvasculature. Am J Physiol 1986;251:H471-H474.
37. Murray MA, Heistad DD, Mayhan WG. Role of protein kinase C in bradykinin-induced increases in microvascular permeability. Circ Res 1991;68:1340-1348.
38. Yong T, Mayhan WG. Effect of prostaglandin E1 on leukotriene C4-induced increases in vascular permeability of hamster cheek pouch. Inflammation 1992;16:159-167.
39. Yong T, Gao XP, Koizumi S, et al. Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. Circ Res 1992;70:952-959.
40. Svensjo E. Characterization of leakage of macromolecules in postcapillary venules. Acta Univ Upsal 1978;34:1-42.
41. Svensjo E, Arfors KE, Raymond RM, Grega GJ. Morphological and physiological correlation of bradykinin-induced macromolecular efflux. Am J Physiol 1979;236:H600-H606.
42. Svensjo E. Bradykinin and prostaglandin E1, E2 and F2 alpha induced macromolecular leakage in the hamster cheek pouch. Prostaglandins Med 1978;1:397-410.
43. Boric MP, Roblero JS, Duran WN. Quantitation of bradykinin-induced microvascular leakage of FITC-dextran in rat cremaster muscle. Microvasc Res 1987;33:397-412.
44. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-776.
45. McVeigh GE, Brennan GM, Johnston GD, et al. Dietary fish oil augments nitric oxide production or release in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:33-38.
46. Smits P, Kapma JA, Jacobs MC, Lutterman J, Thien T. Endothelium-dependent vascular relaxation in patients with Type 1 diabetes. Diabetes 1993;42:148-153.
47. Saenz De Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025-1030.
48. Lash JM, Bohlen HG. Structural and functional origins of suppressed acetylcholine vasodilation in diabetic rat intestinal arterioles. Circ Res 1991;69:1259-1268.
49. Diederich D, Skopec J, Diederich A, Dai EX. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol 1994;266:H1153-H1161.
50. Taylor PD, McCarthy AL, Thomas CR, Poston L. Endothelium-dependent relaxation and noradrenaline sensitivity in mesenteric resistance arteries of streptozotocin-induced diabetic rats. Br J Pharmacol 1992;107:393-399.
51. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991;260:H319-H326.
52. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol 1989;257:H1327-H1333.
53. 2 as an endothelium-derived contracting factor in diabetic state. Diabetes 1993;42:1246-1252.
54. Pieper GM, Langenstroer P, Gross GJ. Hydroxyl radicals mediate injury to endothelium-dependent relaxation in diabetic rat. Mol Cell Biochem 1993;122:139-145.
55. Langenstroer P, Pieper GM. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992;263:H257-H265.
56. Pieper GM, Mei DA, Langenstroer P, O'Rourke ST. Bioassay of endothelium-derived relaxing factor in diabetic rat aorta. Am J Physiol 1992;263:H676-H680.
57. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol 1991;261:H1086-H1094.
58. Pieper GM, Gross GJ. Oxygen free radicals abolish endothelium dependent relaxation in diabetic rat aorta. Am J Physiol 1988;255:H825-H833.
59. Tilton RG, Chang K, Hasan KS, et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993;42:221-232.
60. Corbett JA, Tilton RG, Chang K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-556.
61. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-438.
62. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
63. Wu JT. Advanced glycosylation end products: a new disease marker for diabetes and aging. J Clin Lab Anal 1993;7:252-255.
64. Taylor PD, Wickenden AD, Mirrlees DJ, Poston L. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin induced diabetes: effect of treatment with the aldose reductase inhibitor, ponalrestat. Br J Pharmacol 1994;111:42-48.
65. Knudsen GM, Jakobsen J, Barry DI, Compton AM, Tomlinson DR. Myo-inositol normalizes decreased sodium permeability of the blood-brain barrier in streptozotocin diabetes. Neuroscience 1989;29:773-777.
66. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993;21:205-211.
67. Carrington AL, Calcutt NA, Ettlinger CB, Gustafsson T, Tomlinson DR. Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol 1993;237:257-263.
68. 2) synthesis by aortic rings from rats with streptozotocin-induced diabetes. Prostaglandins Leukotrienes Essential Fatty Acids 1991;44:233-236.
69. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical Biol Med 1994;16:383-391.
70. Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995;25:397-403.
71. Taylor PD, Poston L. The effect of hyperglycemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 1994;113:80-808.
72. Boughton-Smith NK, Deakin AM, Whittle BJR. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. Agents Actions 1992;35(suppl C):C3-C9.
73. Hollis TM, Kern JA, Enea NA, Cosgarea AJ. Changes in plasma histamine concentration in the streptozotocin-diabetic rat. Exp Mol Pathol 1985;43:90-96.
74. Gardner TW, Eller AW, Friberg TR, D'Antonio JA, Hollis TM. Antihistamines reduce blood-retinal permeability in Type I (insulin dependent) diabetic patients with nonproliferative retinopathy: a pilot study. Retina 1995;15:134-140.